Nantahala Capital Management, LLC Unicycive Therapeutics, Inc. Call Options Transaction History
Nantahala Capital Management, LLC
- $2.22 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding UNCY
# of Institutions
31Shares Held
59.9MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA11.4MShares$50.8 Million1.76% of portfolio
-
Great Point Partners LLC Greenwich, CT11MShares$49.1 Million3.87% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$44.7 Million1.9% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$22.7 Million0.56% of portfolio
-
Walleye Capital LLC Plymouth, MN4.09MShares$18.3 Million0.01% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $67.3M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...